Good information. By the way, I like that they have to collect and report that one of the patients suffered an "Arthropod bite" during this study. I am sure that was connected to the pen device somehow...Just humorous is all.
Does anyone find it interesting that the competitor ahead of PFE/OPK has not posted results in a similar fashion?
I could be totally out to lunch here, as I am known to enjoy long lunches (perhaps a siesta too). However, I smell a rat by the way of a lack of transparency with someone who WAS 6 months ahead of Somatrogon. Still waiting to hear what the FDA says, the ultimate arbiter.